pharmacopeia

Doconexent

US-FDASourced from openFDA
GET
/api/v1/drug/doconexent

Boxed warning

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Indications

Sourced from openFDA
  • PNV-DHA is a multivitamin/multimineral nutritional supplement indicated for use in the dietary management of patients with nutritional deficiencies or are in need of nutritional supplementation.

Contraindications

Sourced from openFDA
  • This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.contraindicated

Dosage & administration

Sourced from openFDA

Before, during and/or after pregnancy, one softgel daily or as directed by a physician.

Warnings & precautions

Sourced from openFDA

Ingestion of more than 3 grams of omega-3 fatty acids (such as DHA) per day has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR). Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding.

Adverse reactions

Sourced from openFDA

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
129 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Premature Delivery2217%
  2. 2Maternal Exposure During Pregnancy1512%
  3. 3Nausea86.2%
  4. 4Exposure During Pregnancy75.4%
  5. 5Inappropriate Schedule Of Product Administration75.4%
  6. 6Fatigue64.7%
  7. 7Foetal Exposure During Pregnancy64.7%
  8. 8Pain64.7%
  9. 9Arthralgia53.9%
  10. 10Drug Ineffective53.9%
  11. 11Premature Baby53.9%
  12. 12Pruritus53.9%
  13. 13Vomiting53.9%
  14. 14Abortion Spontaneous43.1%
  15. 15Atrial Septal Defect43.1%

Clinical trials

View JSON

The 1 most recently updated of 1 ClinicalTrials.gov registrations naming Doconexent as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Frequently asked questions

What is Doconexent used for?
According to FDA labeling, Doconexent carries indications including: PNV-DHA is a multivitamin/multimineral nutritional supplement indicated for use in the dietary management of patients with nutritional deficiencies or are in need of nutritional supplementation.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What are the contraindications for Doconexent?
Doconexent labeling lists contraindications including: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.. Always consult the full prescribing information and a clinician.
Note. Data for doconexent is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients